Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)
-
- OSADA Yuki
- Department of Hematology, Fraternity Memorial Hospital
-
- KANAI-SUDO Hikari
- Department of Hematology, Fraternity Memorial Hospital
-
- MIZUKI Taro
- Department of Hematology, Fraternity Memorial Hospital
-
- TANOSAKI Sakae
- Department of Hematology, Fraternity Memorial Hospital
-
- SUZUKI Ken
- Department of Hematology, Fraternity Memorial Hospital
Bibliographic Information
- Other Title
-
- Azacitidine・venetoclax併用「7＋7療法」の安全性と有効性についての検討
Abstract
<p>Acute myelogenous leukemia (AML) has a poor prognosis in patients who are ineligible for intensive chemotherapy. The combination of azacitidine and venetoclax has been shown to have high overall efficiency and remission rates, even in patients ineligible for aggressive chemotherapy. However, myelosuppression is often prolonged after treatment, and infection can also occur. Severe myelosuppression is often addressed by dose titration, but specific dose titration methods have not been clarified. We used the standard induction therapy with azacitidine plus venetoclax, and if blasts decreased to 20% or less, switched to 7+7 therapy to shorten venetoclax to 7 days starting from the next cycle. In the 19 patients we treated (median age 80 years), response rate above MLFS was 100%, CR 57.9%, CRc (CR+CRi) 78.8%, median OS 693 days, median PFS 458 days, and median OS was not reached in previously untreated patients. This indicates that 7+7 is a highly effective and well-tolerated treatment.</p>
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 65 (3), 135-141, 2024
The Japanese Society of Hematology